| Haynesworth et al. (2002) |
0.625-fold, 1.25-fold, 2.5-fold and 5-fold |
HMSC |
Yes |
10% of 1.6 × 106(5 folds over baseline)
|
Not tested |
Not tested |
| Fibroblasts |
Yes |
| Graziani et al. (2006) |
2.5-fold, 3.5-fold and 4.2–5.5-fold (PRP max) |
Osteoblasts |
Yes |
33.3% of 2.5 × ≈ 0.570 × 106
|
33.3% of 2.5 × Ca 0.570 ×106
|
OPG upregulated at 2.5x. OCN and TGF- β1 upregulated at 4.2-5.5x (PRP-max) |
| Fibroblasts |
Yes |
33.3% of2.5 × ≈ 0.570 × 106
|
| Rughetti et al. (2008) |
0.3 ×106, 0.5 × 106, 0.75 ×106, 1,25 ×106, 1.75 ×106, 2.25 ×106, 2.75 ×106, 3.25 ×106, 4. × 106, 5 ×106 and 7 ×106
|
Endothelial cells (umbilical vein) |
Yes |
1.25 × 106(PRP/media ratio unclear)
|
1.5 ×106 (PRP/media ratio unclear) |
Not tested |
| Anitua et al. (2009) |
0.16 ±1 ×106 0.404 ±39 ×106 and 0.767 ±95 ×106/ μ L (2x and 4x of baseline) PRP to media ratio of 20%/80% |
Fibroblasts (skin) |
No |
________ |
Not tested |
Significant increase in collagen I and HA |
| Fibroblasts (synovium) |
Yes |
20% of 0.767 ± 95 × 106and0.404 ± 39 × 106
|
| Fibroblasts (tendon) |
Yes |
20% of 0.767 ± 95 × 106and 0.404 ± 39 × 106
|
| Hsu, Kuo & Tseng (2009) |
1.124 ×106 plt/μ L was added to the wells in concentrations of 2%, 5%, 15%, and 30% |
Fibroblasts (PDL) |
Yes |
5% of 1.124 × 106of5% (Vol/Vol)
|
Not tested |
(Angiogenesis Inhibitor in PRP) |
| Osteoblasts |
| HUVEC |
| Mishra et al. (2009) |
1 ×106/ μ L(non-activated) added to media at ratios of 1%, 5%, 10% and 20% (Vol/Vol) For HMSC only 10% PRP |
Fibroblasts (skin) |
Yes |
10% of 1 × 106
|
Not tested |
Osteogenic marker RUNx2 doubled. Chondrogenic marker Sox-9 mRNA increased tenfold (HMSC) |
| HMSC |
Yes |
| Chen et al. (2012) |
Lysate from PRP of 1.0 × 106 added to media at ratios of 0%, 1%, 5%, 10% lysate (Vol/Vol) |
Dental pulp stem cells |
Yes |
5% of 1.0 × 106
|
Not tested |
(Cell differentiation) |
| Jo et al. (2012) |
0.1, 0.2, 0.4, 0.8, 1, 2, 4, 8 and 16 ×106
|
Tenocytes (rotary cuff) |
Yes |
10% of 4.00 × 106(CaCl2)and10% of 8.00 × 106(CaCl2+ thrombin)
|
Not tested |
Significant increase in collagen I and III and glycosamino-glycan |
| Mazzocca et al. (2012) |
PRPLP: 382.0+/-111.6 ×103/ μ L PRPDS: 472.6+/-224.2 ×103/ μ L PRPHP: 940.1+/-425.8 ×103
|
Myocytes |
Yes |
10% of PRPLP: 382.0+/-111.6 × 103
|
Not tested |
Significantly increased growth factors in all three PRPs. Highest PRPHP(940.1+/- 425.8 ×103/ μ L) |
| Osteoblasts |
Yes |
10% ofPRPDS: 472.6+/-224.2 × 103
|
| Tenocytes |
Yes |
No significance btw PRPLP, PRPDS,and PRPHP
|
| Wang et al. (2012) |
1.2–1.9 ×106/ μ L 1%, 5% and 10% (Vol/Vol) |
Tenocytes |
Yes |
10% of 1.5-1.9 × 106(4x)
|
Not tested |
Significant increased collagen syntesis in 5-1.9 ×106/ μ L (4x) at 10% PRP2 |
| Sadoghi et al. (2013) |
1-, 5-, and 10-fold PRP was obtained by diluting initial PRP in PPP. The PRP/media ratio is unclear. |
Fibroblasts (rotary cuff) |
Yes |
5-fold ≈ 1.25 × 106(PRP/media ratio unclear)
|
Not tested |
(Cell differentiation) |
| Amable et al. (2014) |
2.94+/-1.9 ×106 plt/μ L was mixed with culture media ( α-MEM) to obtain following PRP concentrations: 1%, 2.5%, 5%, 10%, 20%, 30%, 40% and 50% (Vol/Vol) |
HMSC (bone marrow) |
Yes |
10% of 2.94+/-1.9 × 106
|
Not tested |
Various reaction to PRP depending on cell type |
| HMSC (adipose tissue) |
| HMSC (Wharton‘s Jelly) |
| Giusti et al. (2014) |
0.5 ×106, 1 ×106, 2 ×106, 3 × 106 and 5 ×106/ μ L |
Tenocytes |
Yes |
0.5 × 106(PRP/media ratio unclear)
|
0.5 ×106 at 46 h (PRP/media ratio unclear) |
Significant dose-dependent increase in MMP up to 5 ×106/ μ L and collagen I at 1 ×106 and2 ×106/ μ L |
| Tavassoli-Hojjati et al. (2016) |
1.194 ×106/ μ L diluted in DMEM resulting in concentration of 0.1%, 5% and 50%. |
Fibroblasts (periodontal ligament) |
Yes |
5% of 1.194 × 106
|
Not tested |
Not tested |
| Berger et al. (2019) |
Platelet lysate corresponding to platelet levels of 14x, 7x, 3.5x, 1.75x and 0.9x of WB |
Fibroblasts (Achilles, patellar, and palmaris) |
Yes |
20% of0.875 × 106(Young group)
|
______ Old group:3.5 × 106
|
Not tested |
|
20% of3.5 × 106(Old group)
|
| Wang et al. (2019) |
Platelet lysate corresponding to 0.2 ×106, 0.5 ×106, 0.8 ×106, 1.0 ×106, 1.2 ×106, 1.5 ×106, 2.0 ×106, 2.7 ×106, and 3.0 ×106
|
HMSC (bone marrow) |
Yes |
10% of 1.5 to 3.0 × 106
|
Not tested |
(Cell differentiation) |
